<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019626</url>
  </required_header>
  <id_info>
    <org_study_id>CA22747</org_study_id>
    <nct_id>NCT04019626</nct_id>
  </id_info>
  <brief_title>A Study to Assess Tobacco-related Biomarkers of Exposure in Smokers Using myBlu E-cigarettes</brief_title>
  <official_title>An Open-label, Parallel Study to Assess Tobacco-related Biomarkers of Exposure, Biomarkers of Potential Harm, and Nicotine Uptake During a 56-day Switch to Myblu E-cigarettes in Adult Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fontem Ventures BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fontem Ventures BV</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess changes in exposure to selected harmful and
      potentially harmful substances related to tobacco/nicotine use when adult smokers switch from
      their usual brand of combustible cigarettes to the myblu e-cigarette. This study is designed
      as an open-label, partially-randomized, parallel-arm, multi-site study in healthy adult
      smokers.

      Some subjects will be selected to take part in additional procedures as part of a
      pharmacokinetics sub-study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of carboxyhemoglobin in blood</measure>
    <time_frame>56 days</time_frame>
    <description>Change from baseline in the concentration of carboxyhemoglobin (COHb) in whole blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in urine in 24 hours</measure>
    <time_frame>56 days</time_frame>
    <description>Change from baseline in the amount of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL - a biomarker of exposure to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) excreted in urine in 24-hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of 3-hydroxypropylmercapturic acid in urine in 24 hours</measure>
    <time_frame>56 days</time_frame>
    <description>Change from baseline in the amount of 3-hydroxypropylmercapturic acid (3-HPMA - a biomarker of exposure to acrolein) excreted in urine in 24-hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of s-phenyl mercapturic acid in urine in 24 hours</measure>
    <time_frame>56 days</time_frame>
    <description>Change from baseline in the amount of s-phenyl mercapturic acid (S-PMA - a biomarker of exposure to benzene) excreted in urine in 24-hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of nicotine in urine in 24 hours</measure>
    <time_frame>56 days</time_frame>
    <description>The change from baseline in the amount of nicotine equivalents excreted in urine in 24-hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of white blood cells</measure>
    <time_frame>56 days</time_frame>
    <description>The change from baseline in the level of white blood cells, which is a biomarker of potential harm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Measure: Nicotine Withdrawal Symptoms</measure>
    <time_frame>56 days</time_frame>
    <description>Nicotine withdrawal symptoms are measured using the Minnesota Tobacco Withdrawal Scale-Revised (MTWS-R) questionnaire. The DSM-5 and craving items from the MTWS-R have been included. The subjects rate themselves on the questionnaire, which includes symptoms such as angry, irritable, frustrated, depressed mood, restless, insomnia. Each question is rated from 0 (none) to 4 (severe). Total scores may range from 0 to a maximum of 32.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum nicotine concentration in blood</measure>
    <time_frame>180 minutes following the start of product use (11 measurements over the period)</time_frame>
    <description>The maximum nicotine concentration in blood (Cmax)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Continue-smoking</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subject's usual brand of combustible cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>myblu Tobacco Chill 2.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>myblu e-cigarette system with Tobacco Chill flavor Intense Liquidpod, 2.5% nicotine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>myblu Tobacco Chill 4.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>myblu e-cigarette system with Tobacco Chill flavor Intense Liquidpod, 4.0% nicotine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>myblu Honeymoon 2.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>myblu e-cigarette system with Honeymoon flavor Intense Liquidpod, 2.5% nicotine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>myblu Honeymoon 4.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>myblu e-cigarette system with Honeymoon flavor Intense Liquidpod, 4.0% nicotine</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Continue-smoking</intervention_name>
    <description>Ad-libitum use of subjects' usual brand combustible cigarette</description>
    <arm_group_label>Continue-smoking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myblu Tobacco Chill 2.5%</intervention_name>
    <description>Ad-libitum use of myblu e-cigarette with Tobacco Chill flavor 2.5% nicotine</description>
    <arm_group_label>myblu Tobacco Chill 2.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myblu Tobacco Chill 4.0%</intervention_name>
    <description>Ad-libitum use of myblu e-cigarette with Tobacco Chill flavor 4.0% nicotine</description>
    <arm_group_label>myblu Tobacco Chill 4.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myblu Honeymoon 2.5%</intervention_name>
    <description>Ad-libitum use of myblu e-cigarette with Honeymoon flavor 2.5% nicotine</description>
    <arm_group_label>myblu Honeymoon 2.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myblu Honeymoon 4.0%</intervention_name>
    <description>Ad-libitum use of myblu e-cigarette with Honeymoon flavor 4.0% nicotine</description>
    <arm_group_label>myblu Honeymoon 4.0%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having smoked â‰¥5 manufactured combustible cigarettes per day for at least one year

          -  Exhaled carbon monoxide level of &gt;10 ppm at screening

          -  Tested positive for urinary cotinine (approximately 200 ng/mL) at screening

        Exclusion Criteria:

          -  Relevant illness history

          -  Relevant medication use

          -  Body mass index (BMI) of less than 18 kg/m2 or greater than 40 kg/m2

          -  Allergy to propylene glycol or glycerin

          -  Use of nicotine-containing products other than manufactured cigarettes

          -  Use of prescription smoking cessation treatments

          -  Smokers who draw smoke into their mouth and throat but do not inhale

          -  Intent or desire to stop smoking

          -  Female subjects who are pregnant, lactating, or intend to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julie Saathoff</last_name>
    <phone>+1 402 437 4829</phone>
    <email>julie.saathoff@celerion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Saathoff</last_name>
      <phone>402-437-4829</phone>
      <email>julie.saathoff@celerion.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>July 17, 2019</last_update_submitted>
  <last_update_submitted_qc>July 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

